Community-Acquired Pneumonia (CAP) First-Line Empiric Treatment in Adults
The 2019 ATS/IDSA guideline recommends empiric antibiotic selection based on site of care (outpatient vs inpatient) and risk for MRSA and Pseudomonas aeruginosa, with regimen choice guided by local resistance patterns and patient-specific factors. [1]
Medication Selection Algorithm
Outpatient empiric therapy (without MRSA or P. aeruginosa risk)
- Amoxicillin (high-dose amoxicillin) or doxycycline is recommended as first-line. [2]
- A macrolide (eg, azithromycin) is recommended only when pneumococcal macrolide resistance is not a substantial concern. [2]
Outpatient empiric therapy (with comorbidities or increased complexity)
- A regimen of amoxicillin/clavulanate + a macrolide (eg, azithromycin) or amoxicillin/clavulanate + doxycycline is recommended. [2]
Inpatient empiric therapy (without MRSA or P. aeruginosa risk)
- Non-ICU inpatient (no MRSA/Pseudomonas risk): ceftriaxone + azithromycin or ceftriaxone + doxycycline is recommended. [2]
- ICU inpatient (no MRSA/Pseudomonas risk): ceftriaxone (or cefotaxime) + azithromycin or levofloxacin-based therapy is recommended. [2]
Empiric coverage expansion for MRSA and/or P. aeruginosa risk
- When locally validated risk factors for MRSA or P. aeruginosa are present, empiric therapy should add coverage targeted to the risk pathogen(s). [1]
- When MRSA risk is present, empiric therapy should include a non–beta-lactam anti-MRSA agent (eg, vancomycin or linezolid). [2]
- When P. aeruginosa risk is present, empiric therapy should include an anti-pseudomonal beta-lactam (eg, cefepime, piperacillin-tazobactam, or meropenem) combined with an anti-pseudomonal agent from a different class (eg, a fluoroquinolone such as levofloxacin or an aminoglycoside such as tobramycin). [2]
Key Evidence Supporting This Recommendation
The guideline is based on a systematic evidence review and incorporates patient-important outcomes across diagnostic and empiric treatment decisions. [1] A detailed guideline appraisal summarizes the major changes between the 2007 and 2019 ATS/IDSA CAP empiric treatment frameworks. [3]
Monotherapy vs Combination Therapy
- Outpatient without comorbidity or MRSA/Pseudomonas risk: monotherapy with amoxicillin (high-dose), doxycycline, or an appropriate macrolide (only when macrolide resistance is not a major concern) is recommended. [2]
- Outpatient with comorbidity/increased complexity: combination therapy with amoxicillin/clavulanate plus a macrolide or amoxicillin/clavulanate plus doxycycline is recommended. [2]
- Inpatient regimens: combination therapy is used in typical recommended regimens such as a beta-lactam plus either a macrolide or doxycycline in non-ICU settings. [2]
Important Clarifications and Nuances
- Empiric MRSA and P. aeruginosa targeting should be driven by locally validated risk factors, not by the prior historical “healthcare-associated pneumonia” categorization. [3]
- Routine anaerobic coverage for suspected aspiration is not part of the standard CAP empiric framework in the absence of lung abscess or empyema. [2]
Treatment Initiation Thresholds
- Empiric antibiotic therapy should be initiated when the diagnosis of CAP is clinically established, with regimen selection based on outpatient vs inpatient status and MRSA/Pseudomonas risk presence. [1]
- Pretreatment microbiologic testing is recommended for hospitalized patients meeting criteria related to disease severity and/or MRSA/Pseudomonas risk, to support appropriate empiric coverage and de-escalation. [1]
Treatment Duration and De-escalation
- A 5-day course of antibiotics is recommended for CAP when the patient achieves clinical stability (improving vital signs and overall clinical improvement). [4]
Common Pitfalls to Avoid
- Empiric MRSA or P. aeruginosa coverage should not be used without locally validated risk factors, to avoid unnecessary broad-spectrum therapy. [2]
- Macrolide monotherapy should be avoided when pneumococcal macrolide resistance is a substantial concern, because guideline-recommended use depends on resistance being not a major issue. [2]
Target Outcomes of Therapy
- Treatment should achieve clinical stability to support safe early discontinuation or short-course therapy in line with guideline-directed duration. [4]